Compare iShares Silver Trust (SLV) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs Zoetis Inc — how do they compare? iShares Silver Trust trades at $55.04 (market cap $29.02B), while Zoetis Inc trades at $74.43 (market cap $30.20B). The key difference: iShares Silver Trust and Zoetis Inc are close in size by market cap, and Zoetis Inc pays a 2.9% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 89 Days and Zoetis Inc for 70 Days on average.
| SLV | ZTS | |
|---|---|---|
Market Cap | $29.02B | $30.20B |
Volume | 16,510,334 | 6,175,327 |
52-Week High | $105.57 | $147.53 |
52-Week Low | $42.40 | $69.09 |
Typical Hold Time | 89 Days | 70 Days |
Sector | — | Health |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV trades at $54.85, up 1.91% with bearish technical signals from moving averages but oversold RSI readings. The ETF shows minimal operational activity with $0 revenue and $2.17M net income in 2024, while assets surged to $13.4B from previous years. Recent news highlights silver's volatility amid Fed policy uncertainty and rising Treasury yields.
Outlook remains cautious due to bearish technicals and macroeconomic pressures on precious metals. Investment opportunity exists for contrarian buyers given oversold conditions, but risks include continued Fed tightening and dollar strength. Silver's dual role as monetary and industrial metal adds volatility exposure.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
